Clinical Trials
7 trialsNCT01746979 2025-05-11
MAESTRO
ImmunoGenesis
Phase 3 Completed
NCT02047500 2025-05-11
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
ImmunoGenesis
Phase 1 Terminated
NCT06782555 2025-01-21
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
ImmunoGenesis
Phase 1/2 Recruiting
NCT02402062 2020-07-27
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01833546 2018-10-15
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03098160 2017-10-30
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Threshold Pharmaceuticals
Phase 1 Unknown
NCT00743379 2015-05-07
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
Threshold Pharmaceuticals
Phase 1/2 Completed